Abbvie Inc ABBV

$274.36 -6.76 (-2.40%)

Valuation

Market cap
496,680,832,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
25.43
Forward PE
19.83
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
6,409,500
Avg volume
4,579,406
Day's range
$273.70 – $283.43
Shares out
1,766,793,000
Stochastic %K
65%
Beta
0.24
Analysts
Strong Sell
Price target
$281.70

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

PanicSeller8 Oct 14, 2:22 PM
$ABBV Always keep it among my top 5-7 holdings.
0 replies
Albino_Trader123 Oct 14, 1:51 PM
$LLY $PFE $ABBV money going into safe names
0 replies
SellasgpsCurativeBAT11 Oct 14, 12:41 PM
$ABBV $AZN $JNJ $PFE $SLS Conclusion: Sellas is No longer a data play but Outright BO Play in active negotiations. Sellas is in the middle of active, good-faith merger or acquisition negotiations, premature disclosure of unblinded clinical data could disrupt or collapse the deal. Withholding the data to protect the transaction is considered a valid corporate purpose under SEC guidelines. The potential buyer and Sellas negotiators must be bound by strict Non-Disclosure Agreements (NDAs). Often, the data is shared only with a restricted "clean team" or through a secure virtual data room to prevent leaks. 🤐✌️❤️‍🩹 When the silence 🤐 is Broken, $SLS won’t be a stand alone Co. but part of Big pharmaceutical suitor. I expect a T1 halt before ultimate BO PR. Victory lap at ASH 2026. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 14, 12:20 PM
$ABBV $AZN $JNJ $PFE $SLS Most Dangerous Biotechnology Stock to short EOY 2026. Part 3 continued. 19. Sellas M&A discussions, Sellas and potential Big Pharma buyers would operate under strict Non-Disclosure Agreements (NDAs). Sharing Phase 3 data in a private "data room" with an acquirer does not violate Regulation FD because the acquirer is bound by a duty of trust and confidentiality. 20. Finally, In biotech M&A, unblinded Phase 3 data is the ultimate binary catalyst. Acquirers often demand to see this data as part of deep due diligence before finalizing an acquisition premium, and a company may legally withhold it from the general public for a limited window while a definitive agreement is being hammered out. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 14, 11:55 AM
$SLS $JNJ $PFE $ABBV $AZN Part 2. 11. Institutional Shares Ownership(Long) 90,972,079 - 45.05% 12. GPS Regal Phase 3 study Breakthrough success master Key to unlock 20+ other WT1 Platform indications= $40BILLION + World wide revenues potential. 13. SLS009 (tambiciclibBlockbuster data to date better than any CDK9 in production right now. 14. J&J executives openly touting GPS as Game changing cancer treatment in AML. 15. AZN Executives openly touting GPS as Breakthrough Cancer treatment. 16. Down to 11 Time Employees now from 13 during QP. 17. Sellas Extremely lean Co. for outright BO. 18. ASH 2026 Huge Booth for potential Victory lap for LBA GPS Breakthrough data+ BO! ✌️🙏❤️‍🩹
1 replies
thatsolardude365 Oct 14, 7:57 AM
$ABBV: the lead plaintiff in Garcia v. AbbVie says she paid thousands out of pocket for Juvederm in 2023, then was hospitalized 3 years later from alleged delayed granulomas. No class certified, nothing to claim. Open Class Actions.
0 replies
biolover Oct 14, 12:56 AM
$VKTX vk2735 is much more derisked now vs March 2024 when it was $10 B. Not sure what the worry if no margin ? Obviously many people get there as it is popular obesity but with some difficulty in understanding the asset. The maintenance data sort of derisked phase 3. If DC rate due to AEs only 1% ( even if higher ) under rapid escalation and vomit only 26% , we are going to have good tolerability in phase 3 .. and efficacy looks excellent. Not all institutions can clearly see that. Last 2 years been tough and CEO takes part of blame but he got the business into a stable shape now with 4 phase 3 , plenty of supply and clear commercial plan ( although we don’t know all details ) .. I think $LLY is the one that needs to worry in 2028 and beyond. This biotech crisis will pass. Most BP is under pressure. Even $LLY and $ABBV
0 replies
55X_ROI_Q1_2026 Oct 13, 7:32 PM
$SLS $2.5B $MRNA The Share Price will continue climbing until we get the Registrational Phase 3 Results and then the share Price Launches. - the Positive P3 Result is worth Close to $50B to Big Pharma - Don't be Surprised when this rigged $2.5B Mcap is $25B / $125 per share and Climbing, for the same reason $MRNA ran from $20 to $225 and added $50B in market value in the days after its Phase 3 Cancer vaccine results were announced. $ABBV • Imminent 80th Event PR and GPS P3 Results • Gps Immunotherapy is getting Fda GREENLIGHT to Treat 50,000 Patients Each year + 100,000 AML patients CURRENTLY in Remission - 100,000 right out of the GATE. • The Co Estimated a Minimum of $300K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev for 5+ Years. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $125 Per Share.
0 replies